BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
BEECH：一项剂量探索性导入研究，随后开展一项随机 II 期研究，评估 AKT 抑制剂 capivasertib (AZD5363) 联合紫杉醇治疗雌激素受体阳性晚期或转移性乳腺癌患者以及 PIK3CA 突变亚群的疗效。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz086
Turner, N C; Alarcón, E; Armstrong, A C; Philco, M; López Chuken, Y A; Sablin, M-P; Tamura, K; Gómez Villanueva, A; Pérez-Fidalgo, J A; Cheung, S Y A; Corcoran, C; Cullberg, M; Davies, B R; de Bruin, E C; Foxley, A; Lindemann, J P O; Maudsley, R; Moschetta, M; Outhwaite, E; Pass, M; Rugman, P; Schiavon, G; Oliveira, M
